Metastatic Cancer clinical trials

A test to find the best drugs for advanced colorectal cancer

This trial uses a special test to help choose which drugs might work best for you if you have metastatic colorectal cancer that has stopped responding to first treatment. The goal is to match you with a more effective next therapy.

Testing a new drug for metastatic prostate cancer

This trial tests an investigational drug (AZD0516) alone or with other treatments in men with prostate cancer that has spread to other parts of the body and is no longer responding to hormone therapy. It aims to see if the drug can help control the cancer.

New drug vs chemo for KRAS G12D pancreatic cancer

This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.

Second-line chemo for advanced colorectal cancer

This study looks at different chemotherapy options for people with metastatic colorectal cancer that has stopped responding to first treatment. It aims to find which second-line approach works best.

Comparing two drug combos for first-line metastatic colorectal cancer

This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.

Continuing cetuximab after first treatment stops working for metastatic colorectal cancer

This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.

JS212 Combination for Untreated Metastatic Colorectal Cancer

This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.

New combination therapy for advanced colorectal cancer after first treatment

This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.

Dalpiciclib With Anti-HER2 and Hormone Therapy for Advanced Breast Cancer

This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.

New imaging tracer for metastatic prostate cancer

This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

JANX014 for Advanced Prostate Cancer

This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.

AU-007 antibody for hard-to-remove or spread skin and lung cancers

This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.

Abemaciclib before PSMA cancer therapy for advanced prostate cancer

This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.

RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer

This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.

Genotype-guided chemo for metastatic pancreatic cancer

This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.

Chemo for prostate cancer with DNA repair changes

This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.

Liver-directed chemo with standard chemo for breast cancer

This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.

Lab study using mini-tumors to test prostate cancer treatments

This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.

Radiation timing options for low-burden metastatic prostate cancer

This study compares different radiation schedules to the main prostate tumor in men with low-burden metastatic (spread) hormone-sensitive prostate cancer. It may help find a radiation timing approach that controls the cancer while balancing side effects.

Study of experimental drug combo for advanced cancers

This trial tests a new combination of three drugs—evofosfamide, zalifrelimab, and balstilimab—in people with advanced prostate, pancreatic, or certain head and neck cancers that have stopped responding to standard treatments.

HER3-DXd for Advanced Breast Cancer After T-DXd

This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.

177Lu-PSMA-617 for advanced prostate cancer with bone spread

This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.

Study of SYS6043 for advanced or metastatic solid tumors

This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.